PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2023-03-02

Date Title Company
02-Mar-2023 MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical Businesswire
02-Mar-2023 Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023 Businesswire
02-Mar-2023 Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 Businesswire
02-Mar-2023 Medidata Drives Diversity in Clinical Trials, Passing 30,000 Studies and 9 Million Participants Businesswire
02-Mar-2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 Businesswire
02-Mar-2023 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
02-Mar-2023 Spine Pain Market is expected to garner a value of US$ 12.47 Billion by 2033 MARKITWIRED
02-Mar-2023 Durable Medical Equipment Rental Market is expected to reach US$ 47 billion by 2033 MARKITWIRED
02-Mar-2023 Edward’s Syndrome Treatment Market is expected to reach US$ 7.98 Billion by 2033 MARKITWIRED
02-Mar-2023 Filariasis Treatment Market to reach US$ 28.68 Billion by 2033, at a CAGR 10.1% MARKITWIRED
02-Mar-2023 Expansion Therapeutics Announces Key Additions and Updates to Scientific Advisory Board Businesswire
02-Mar-2023 I-care’s Strategic Alliance with Technical Associates of Charlotte Boosts Predictive Maintenance Expertise Businesswire
02-Mar-2023 MMI Named One of Fast Company’s 2023 “World’s Most Innovative Companies” Businesswire
02-Mar-2023 Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company Businesswire
02-Mar-2023 JATT Acquisition Corp’s Proposed Business Combination With Zura Bio Limited Declared Effective by US SEC Businesswire
02-Mar-2023 FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma Businesswire
02-Mar-2023 Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution) Businesswire
02-Mar-2023 Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023 Businesswire
02-Mar-2023 The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor Businesswire
02-Mar-2023 Stevanato Group Reports Fourth Quarter and Fiscal Year 2022 Financial Results Businesswire